Albany Molecular Research, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Albany Molecular Research, Inc.
Founded with a vision to change point-of-care diagnostics, Osler Diagnostics has raised nearly $200m to develop and commercialize a platform that promises to revolutionize diagnostics with just a drop of a patients’ blood.
Plus deals involving Dong-A/Polifarma, Intas/Syna, Kissei/Synmosa, Ono/Memo, Takeda/Shionogi, Fosun/Lilly and JW Therapeutics/2seventy bio.
Private Company Edition: The Paragon Biosciences-founded Emalex previously raised $35m when ecopipam was in Phase II. Also, Catalio Capital launches a “special situations” fund, Zenas raises $118m to develop a pipeline of autoimmune disease treatments and Lusaris emerges with $60m.
The Danish group put the 5-HT6 antagonist on the shelf after three failed late-stage trials but Denovo believes that idalopirdine could still work for a subset of Alzheimer's patients.
- Contract Research, Toxicology Testing-CRO
- Laboratory Testing Services
- Generic Drugs
Drug Discovery Tools
- Drug Discovery Tools
- Other Names / Subsidiaries
- Cedarburg Pharmaceuticals, Inc.
- Excelsyn Ltd.
- Hyaluron Inc.
- Gadea Pharmaceutical Group (Crystal Pharma)
- Prime European Therapeuticals S.p.A. (Euticals)